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Abstract: Natural products from marine origin constitute a very promising and underexplored source
of interesting compounds for modern biotechnological and pharmaceutical industries. However,
their evaluation is quite challenging and requires specifically designed assays to reliably identify
the compounds of interest in a highly heterogeneous and interfering context. In the present study,
we describe a general strategy for the confident identification of tight-binding protease inhibitors in
the aqueous extracts of 62 Cuban marine invertebrates, using Plasmodium falciparum hemoglobinases
Plasmepsin II and Falcipain 2 as model enzymes. To this end, we first developed a screening strategy
that combined enzymatic with interaction-based assays and then validated screening conditions
using five reference extracts. Interferences were evaluated and minimized. The results from the
massive screening of such extracts, the validation of several hits by a variety of interaction-based
assays and the purification and functional characterization of PhPI, a multifunctional and reversible
tight-binding inhibitor for Plasmepsin II and Falcipain 2 from the gorgonian Plexaura homomalla,
are presented.
Keywords: tight-binding protease inhibitor; combined screening strategy; Plasmepsin II; Falcipain 2;
Plasmodium falciparum
1. Introduction
Proteases are enzymes that catalyze the hydrolysis of peptide bond in proteins and peptides [1].
Given that protein functions are dynamic in nature, they eventually undergo proteolytic processing
at some point for maturation, inactivation or turnover purposes [1,2]. This fact confers to proteases
an exceptional importance as functional class, provided that proteins control many aspects of cell life.
Thus, proteases are involved in the control of a large number of key physiological processes, such
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as cell-cycle progression, cell proliferation and cell death, DNA replication, tissue remodeling, cell
nutrition and signaling, immune/defensive response and pathogens invasion, among others [2,3].
Due to its high catalytic efficiency in hydrolyzing protein substrates, protease activity must be
tightly regulated in vivo to avoid unwanted, unspecific or uncontrolled detrimental proteolysis.
Thus, protease inhibitors, their natural counterparts, are also key physiological actors involved in a
wide variety of normal, pathological and infectious processes by modulating the activity of specific
protease targets [4]. Consequently, protease inhibitors have become irreplaceable molecules not only
as biochemical tools for the basic study of proteases, but also as drugs for the treatment of numerous
chronic and infectious human diseases [2]. In addition, protease inhibitors have found applications in
many other fields, including biotechnology, agriculture and food industries [5].
During its intraerythrocytic residence, Plasmodium falciparum, the most virulent human malaria
species, degrades massive amounts of host hemoglobin [6]. Hemoglobin catabolism occurs within an
acidic organelle called digestive vacuole and is considered a critical process for P. falciparum survival [7].
This represents a complex proteolytic cascade performed by multiple proteases (both, exo- and
endopeptidases) of different mechanistic classes (including cysteine, aspartic, and metallo proteases),
which act coordinately and cooperatively to hydrolyze hemoglobin to amino acids [7,8]. Among the
active aspartic hemoglobinases identified in P. falaciparum, Plasmepsin II (Plm II) has been the most
important and best characterized. It belongs to Clan AA family A1 and shows all the typical structural
and functional characteristics of pepsin-like enzymes [9–11], thus constituting a valuable model for
this important group. Similarly, three cysteine hemoglobinases called Falcipains (FP2, FP2′ and FP3)
occur within P. falciparum digestive vacuole. FP2 (gene ID PF11_0165) is the most abundant and best
characterized, showing all the structural and functional properties of archetypical papain-like cysteine
peptidases (Clan CA family C1) [12]. In addition to hemoglobin digestion, FP2 is involved in the
proteolytic activation of pro-plasmepsins [13] and the release of parasites from red blood cells by
degrading erythrocyte membrane skeletal proteins, including ankyrin and the band 4.1 protein [14,15].
Given its direct implication in critical parasite processes, Plm II and FP2 were considered for many years
as promising chemotherapeutic targets and numerous tight-binding inhibitors classes were developed
for both enzymes [16–20]. However, knockout parasite studies have probed both enzyme activities as
redundant and/or non-essential for parasite survival in different contexts and parasite developmental
stages [21–23], indicating that active Plm II and FP2 inhibitors reducing P. falciparum viability were
likely operating through other (truly essential) targets and/or mechanisms of action. Despite this
fact, a considerable amount of biochemical knowledge and research tools were generated around both
enzymes during the last two decades. These include: efficient recombinant expression systems [24,25],
crystallographic structures bound to different ligands [26,27], specific substrates and inhibitors [28,29],
different kinds of High-Throughput Screening enzymatic assays [30–32], computational models for
the virtual screening of compounds [28,33] and biophysical techniques for their characterization.
This makes Plm II and FP2 exceptionally well characterized model enzymes for virtually any kind of
scientific investigation.
Marine invertebrates constitute a vast and mainly unexplored source of bioactive molecules,
from which have been isolated in the last decades novel compounds with biomedical and
biotechnological interest [34–36]. Protease inhibitors have also been found abundantly in marine
invertebrates [37], as part of mechanisms of chemical defenses against predation, niche displacement
or associated with innate immune responses in these organisms [38,39]. Both peptidic and non-peptidic
protease inhibitors isolated from marine invertebrates have shown unique features regarding their
stability, enzyme specificity and tight-binding affinity (Ki ≤ 10−7 M) for their targets [40–45],
anticipating a variety of potential applications. Given the high density and biodiversity of marine
invertebrates, especially those from ecosystems of the tropical Caribbean Sea, it might be expected that
aqueous extracts of Cuban marine invertebrates could be a valuable source of new tight-binding
inhibitors for Plm II and FP2 with biomedical and/or biotechnological importance. Therefore,
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the ability to unambiguously identify those extracts containing the most promising inhibitors for
both proteases is important to the research in natural products and the modern industry.
The main analytical approach for the identification of protease inhibitors in natural extracts has
been the evaluation of inhibitory activity by using typical enzyme-specific activity assays [42,44,46,47]
and to a lesser degree, interaction-based assays which sense directly the binding to the target enzyme.
Enzymatic activity assays are inexpensive, high-throughput capable and provide direct information
about the inhibitory effect of the extract components on the activity of the target enzyme [48]. However,
they are prone to the generation of false positive hits due to the complex chemical composition of
the extracts interfering with the assay (e.g., changes in pH or ionic strength, presence of competing
substrates or enzymes, colored/fluorescent components affecting assay readout, etc.) during screening
of crude extracts. In contrast, interaction-based assays, such as affinity chromatography [46,49],
Surface Plasmon Resonance (SPR)-biosensors [50] or Intensity Fading (IF) Matrix Assisted Laser
Desorption/Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF MS) [51,52], provide reliable
information about the presence of target interactors even in the highly heterogeneous context of
natural extracts. Nevertheless, they have been rarely used for the identification of protease inhibitors
in these sources.
In this study, we screened aqueous extracts of Cuban marine invertebrates for tight-binding
inhibitors of Plm II and FP2 as model enzymes of the aspartic (Clan AA family A1) and
cysteine (Clan CA family C1) classes. To this end, we developed a comprehensive strategy that
combines enzymatic activity assays (for the identification and prioritization of extracts) and different
interaction-based methodologies (for the validation of positive hits and elimination of false positives).
In a first stage, the screening conditions were established and validated using a small group of
already-known (reference) extracts. Then, the selected conditions were used to screen 62 marine extracts
belonging to different Phyla, leading to the confident identification of several extracts containing
simultaneously tight-binding Plm II and FP2 inhibitors.
2. Results
2.1. Design and Validation of a Two-Round Screening Strategy Using Five Reference Extracts of Marine Organisms
To reduce the occurrence of false positive hits during the screening of tight-binding Plm II and
FP2 inhibitors in natural extracts, we developed a two-round strategy combining enzymatic and
interaction-based assays (Figure 1). Previous to the large-scale evaluation of more than 60 marine
invertebrate extracts from Cuban coasts, we performed a validation experiment with five reference
extracts, previously characterized in our lab as positives (+) or negatives (−) for inhibition against
Plm II, FP2 and other related enzymes [46,47,53]: Plexaura homomalla (Plm II+/FP2+), Phallusia nigra
(Plm II−/FP2−), Stichodactyla helianthus (Plm II+/FP2+), Xestospongia muta (Plm II+/FP2−) and
Polyclinum constellatum (Plm II−/FP2−).
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Figure 1. Two‐round combined  strategy designed  for  the confident  identification of  tight‐binding 
protease  inhibitors  in complex natural extracts. Enzymatic activity assays, ordered as primary and 
secondary screening steps, allow the identification and prioritization of those extracts that potently 
inhibited  the  proteases  of  interest, whereas  the  interaction‐based  assays  allow  the  validation  of 
positive hits and the elimination of false positives prior to bio‐guided fractionation. 
2.1.1. Reduction of Interference Caused by Raw Extracts on Enzymatic Assays 
Initially, we assessed the robustness of the enzymatic assays in the presence of the crude extracts. 
Raw extracts caused significant substrate degradation in the absence of the target enzymes (Figure 
2A,B) and  in many cases, also  the  formation of  insoluble material,  thus proving unsuitable  to be 
directly  analyzed.  A  clarification  treatment  was  introduced  to  reduce  the  general  chemical 
heterogeneity of the extracts and their endogenous proteolytic activity in particular, as it may lead to 
the occurrence of  false negatives  [54]. Heat  clarification  (60  °C,  30 min)  effectively  reduced both 
chemical  complexity  and  proteolytic  activity  to  levels  compatible with  the  assays  in  80%  of  the 
extracts  (Figure  2),  although  two  heat‐clarified  extracts  remained  active  against  the  reporter 
substrates, probably due to the persistence of thermo‐stable proteolytic activity [47]. TCA treatment 
(5% final concentration) proved to be more efficacious in eliminating recalcitrant proteolytic activities 
(100% assay compatibility), although required further time consuming dialysis and re‐concentration 
steps. 
Figure 1. Two-round combined strategy designed for the confident identification of tight-binding
protease inhibitors in complex natural extracts. Enzymatic activity assays, ordered as primary and
secondary screening steps, llow the id ntification and prioritization of those extracts th t pote tly
inhibited the proteases of int rest, whereas the interaction-based assays allow the validation of positive
hits and the elimination of false positives prior to bio-guided fractionation.
2.1.1. Reductio of Interference Caused by Raw Extracts on Enzymatic Assays
Initially, we assessed the robustness of the enzymatic assays in the presence of the crude extracts.
Raw extracts caused significant substrate degradation in the absence of the target enzymes (Figure 2A,B)
and in many cases, also the formation of insoluble material, thus proving unsuitable to be directly
analyzed. A clarification tre tme t was introduc d to reduce the general chemical het rog neity of the
extracts and their endogenous proteolytic activi y n particu ar, as it may lead to the occurrence of als
negatives [54]. Heat clarification (60 ◦C, 30 min) effectively reduced both chemical complexity and
proteolytic activity to levels compatible with the assays in 80% of the extracts (Figure 2), although two
heat-clarified extracts remained active against the reporter substrates, probably due to the persistence
of thermo-stable proteolytic activity [47]. TCA treatment (5% final concentration) proved to be
more efficacious in eliminating recalcitrant proteolytic activities (100% assay compatibility), although
required further time consuming dialysis and re-concentration steps.
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Figure  2.  Interference  levels  caused  by  crude,  heat‐  and  TCA‐clarified  reference  extracts  on  the 
enzymatic assays. (A) Intrinsic proteolytic activity of crude and clarified extracts (final dilution 1/2) 
on the immobilized peptidic substrate DU2 under Plm II enzymatic assay conditions (2 h at 37 °C in 
buffer 100 mM NaAc, pH 4.7). The proposed threshold for substrate degradation of 30% is indicated 
by a dashed line. (B) Intrinsic proteolytic activity of crude and clarified extracts (final dilution 1/20) 
on the fluorogenic substrate Z‐FR‐AMC (12.5 μM) under FP2 enzymatic assay conditions (buffer 100 
mM NaAc, 10 mM DTT pH 5.5 buffer). The proposed threshold for intrinsic substrate degradation 
(∂F/∂t ≥ 5 × 10−4 AFU∙s−1) is indicated by a dashed line. (C) Effects of crude and clarified extracts (final 
dilution 1/20) on fluorescence readouts (λexc/λemss = 355 nm/460 nm) of the AMC standard. The limit 
for  non‐significant  quenching  effect  (Q  =  FAMC/FAMC  +  EXT  =  1)  is  indicated  by  a  dashed  line.  The 
experiments were all performed in triplicate. 
Previous to the evaluation with enzymatic assays, we also assessed the effect of crude, heat‐ and 
TCA‐clarified  reference  extracts  on  the  fluorescence  readout  of  a  standard  of AMC. At  the  final 
dilution of 1/5 and 1/10, the vast majority of the extracts were able to quench the fluorescence of AMC 
independently  of  the  clarification  treatment  (data  not  shown);  probably  due  to  the  presence  of 
pigments in the extracts [55]. Since this would cause an artificial decrease in the slope of enzymatic 
assay (mimicking the presence of a true inhibitor), it was necessary to use a final dilution (1/20) in the 
enzymatic assay  such  that  the  fluorescence quenching was not  significant  (Q = FAMC/FAMC+EXT  ≈ 1) 
(Figure 2C). Heat and TCA clarification treatments caused only a modest decrease in the observed 
quenching of AMC fluorescence, both reducing by 50% the number of extracts causing significant 
assay  interferences. Even  at  the  1/20 dilution, P.  homomalla  heat‐  and TCA‐clarified  extracts  still 
reduced significantly the fluorescence of AMC. In these cases, the calculated coefficient Q was used 
to correct the deviation of experimental assay slope. 
2.1.2. Screening for Tight‐Binding Inhibitors Using Specific Activity Assays and Selection of Positive 
Hit Threshold 
To favor the identification of those extracts with higher potential in terms of inhibitor potency 
and/or concentration, non‐typical enzymatic assay conditions were adopted. First, we used relatively 
Figure 2. Interference levels caused by crude, heat- and TCA-clarified reference extracts on the
enzymatic assays. (A) Intrinsic proteolytic activity of crude and clarified extracts (final dilution 1/2) on
the immobilized peptidi substrate DU2 un er Plm II enzym ic ass y c ditions (2 h 37 ◦C in
buffer 100 mM NaAc, pH 4.7). The proposed threshold for subst at degradation of 30% is indicated
by a dashed line. (B) Intrinsic proteolytic activity of crude and clarified extracts (final dilution
1/20) on the fluorogenic substrate Z-FR-AMC (12.5 µM) under FP2 enzymatic assay conditions
(buffer 100 mM NaAc, 10 mM DTT pH 5.5 buffer). The proposed threshold for intrinsic substrate
degradation (∂F/∂t ≥ 5 × 10−4 AFU·s−1) is indicated by a dashed line. (C) Effects of crude and
clarified extracts (final dilution 1/20) on fluorescence readouts (λexc/λemss = 355 nm/460 nm) of the
AMC standard. The limit for non-significant quenching effect (Q = FAMC/FAMC + EXT = 1) is indicated
by a dashed line. The experiments were all performed in triplicate.
Previous to the evaluation with enzymatic assays, we also assessed the effect of crude, heat-
and TCA-clarified ref ren e extracts on the fluorescence readout of standard of AMC. A the final
dilution of 1/5 and 1/10, the vast majority of the extracts were able to quench the fluorescence of
AMC independently of the clarification treatment (data not shown); probably due to the presence of
pigments in the extracts [55]. Since this would cause an artificial decrease in the slope of enzymatic
assay (mimicking the presence of a true inhibitor), it was necessary to use a final dilution (1/20) in the
enzymatic assay such that the fluorescence quenching w not significant (Q = FAMC/FAMC+EXT ≈ 1)
(Figure 2C). Heat and TCA clarification treatments caused only a modest decrease in the observed
quenching of AMC fluorescence, both reducing by 50% the number of extracts causing significant assay
interferences. Even at the 1/20 dilution, P. homomalla heat- and TCA-clarified extracts still reduced
significantly the fluorescence of AMC. In these cases, the calculated coefficient Q was used to correct
the deviation of experimental assay slope.
2.1.2. Screening for Tight-Binding Inhibitors Using Specific Activity Assays and Selection of Positive
Hit Threshold
To favor the identification of those extracts with higher potential in terms of inhibitor potency
and/or concentration, non-typical enzymatic assay conditions were adopted. First, we used
relatively high concentrations of the target enzymes (0.37 µM and 0.95 µM for Plm II and FP2,
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respectively) for enzymatic screening. Tight-binding inhibitors display their maximal inhibitory
efficiency (i.e., linear dose-response curves known as titrating behavior) when reaction conditions are
such that [E0]/K
app
i ≥ 10 [56]. Consequently, the extracts containing tight-binding inhibitors showing
Kappi ≤ [E0]/10 (3.7 × 10−8 M for Plm II and 9.5 × 10−8 M for FP2) should display distinctive linear
dose–response curves in our assays. Thus, the parameter [E0] established the threshold for inhibitor
“potency” desired in the final output of the enzymatic screening. Secondly, we set the concentration of
FP2 substrate around the KM value, as it equalizes the chances to identify competitive, non-competitive
and uncompetitive inhibitors [57,58]. This was not necessary for Plm II assay, since E-I equilibrium is
not affected by the immobilized substrate DU2 [31,59].
These screening settings were subjected to validation by using the previously characterized
reference extracts (Figure 3). Different levels of inhibitory activity were obtained for all clarified
extracts against both enzymes. As expected, the clarified extracts of P. homomalla and S. helianthus
showed high inhibitory activities against both enzymes, whereas P. nigra and P. constellatum showed
only marginal inhibition. In the case of X. muta, we expected to find significant Plm II inhibitory
activity in the heat-clarified extract [46]. Instead, a negative inhibition (which means increased substrate
degradation in comparison with assay control) was observed. The intrinsic proteolytic activity present
in the extract (Figure 2A) masked the identification of target-specific inhibitory activity, representing
a false negative case. Thus, we established a threshold for intrinsic proteolytic activity in clarified
extracts to be less than 30%–35% of the activity of control enzyme.
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TCA‐ and heat‐clarified extracts on the activity of: Plm II (A); and FP2 (B) (primary screening). For 
both  assays,  extracts  causing  reduction  levels  equal  or  higher  to  75% were  considered  hits. Hit 
thresholds are indicated by dashed lines. The experiments were all performed in triplicate. 
In addition, we established a rather high hit threshold: reduction of 75% of the enzymatic activity 
of the control, as it allowed both the identification of the seven most active extracts from the eight 
positive extracts included and the rejection of all negative and marginally inhibitory extracts (Figure 3). 
It is intuitively expected that the more stringent the selection criterion used, the lower the number of 
hits detected and concomitantly, the lower the probability of finding false positives. On the contrary, 
if a less stringent selection criterion is used, a higher number of hits are expected to be obtained, but 
also with higher probability that a non‐active compound might be  included by chance. Therefore, 
this parameter  sets  the  level  for  “confidence”  in  the output of  enzymatic  screening, but  also  the 
desired inhibitor “quantity” in positive extracts. Under the titrating conditions previously established 
in our assays, virtually all  the  tight‐binding  inhibitor present will be  in  the  form of E‐I complex. 
Therefore, if all the reduction in proteolytic activity of the target enzyme is actually due to inhibition, 
it might be expected that the global inhibitor concentration acting on target enzyme must be at least 
Figure 3. Enzymatic screening of Plm II and FP2 inhibitory activity in the reference extracts. Effect of
TCA- and heat-clarified extracts on the activity of: Plm II (A); and FP2 (B) (primary screening). For both
assays, extracts causi g reduction levels equal or higher to 75% were considered hits. Hit thresholds
are indicated by dashed lines. The experiments were all performed in triplicate.
In addition, we established a rather high hit threshold: reduction of 75% of the enzymatic activity
of the control, as it allowe both the identification of the seven most active extracts from the eight
positive extracts inclu ed and he rejecti n of all neg t ve and mar inally inhibitory extracts (Figure 3).
It is intuitively expected that the more stringent the selection criterion used, the lower the number of
hits detected and concomitantly, the lower the probability of finding false positives. On the contrary,
if a less stringent selection criterion is used, a higher number of hits are expected to be obtained,
but also with higher probability that a non-active compound might be included by chance. Therefore,
this parameter sets the level for “confid nce” in the outpu of nzymatic s reening, but also the desired
inhibitor “quantity” in positive extracts. Under the titrati g conditions previously established in our
assays, virtually all the tight-binding inhibitor present will be in the form of E-I complex. Therefore,
if all the reduction in proteolytic activity of the target enzyme is actually due to inhibition, it might
be expected that the global inhibitor concentration acting on target enzyme must be at least 0.75*[E0];
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i.e., 0.28 µM and 0.71 µM for Plm II and FP2 assays, respectively. In this sense, the rejection of low
potential extracts is compensated by the significant reduction in false positives rates.
2.1.3. Confirmatory Interaction Assays Using Affinity Chromatography, SPR and IF MALDI-TOF MS
Both positive and negative extracts were then subjected to confirmatory experiments by using
affinity chromatography as a reference interaction-based assay. Typical affinity profiles were obtained
for the evaluation of P. homomalla (TCA) and X. muta (heat) clarified extracts on a Plm II-Sepharose
matrix (Figure 4A,B), with the eluted fraction showing ~6-fold and 10-fold increase in the specific
inhibitory activity, respectively [46]. Interaction of P. homomalla (heat) and S. helianthus (heat)
positive extracts with clan CA family C1 enzymes were confirmed in the same way by the use
of a Papain-Sepharose matrix (Figure 4C,D) [53]. In contrast, both affinity resins failed to concentrate
specific inhibitory activity for P. constellatum (TCA), X. muta (TCA) and P. nigra (TCA) extracts (Figure S1,
Supplementary Material), confirming the absence of tight-binding inhibitors of the target enzymes.
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We g in d further access to perform more sophisticated bindi g a says to some of those samples,
such as SPR and IF MALDI-TOF MS, which are well-establi hed and robust technologies to analyze
protease-inhibitor interactions [52,60]. Optical Biosensor analyses were performed either using
Biacore (Biacore AB, Uppsala, Sweden) (Plm II) or IAsys (ThermoLab-Systems, Cambridge, UK)
(FP2) instruments, by directly immobilizing target proteases for the evaluation of serial dilutions of
two reference extracts: P. homomalla (heat) as positive control and X. muta (TCA) as negative control.
At this poin , the global concentration of tig t-binding inhibitors active against Plm II and FP2
in the clarified extracts was estimated by titration ith enzymes of known concentration. Given that
the number, nature and features of the different inhibitor species present in the extracts were a priori
unknown, this represented the only resource at hand to quantify the amount of functionally active
inhibitors. Although this procedure did not allow us to quantify the concentration of individual
inhibitors (protein isoforms, etc.), it showed three major advantages: (1) it allowed discriminating
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between tight-binding (those we intend to identify) and classical inhibitors (low biomedical potential);
(2) unfolded or denatured inhibitor molecules (generated during extraction and/or clarification
treatment) are not detected; and (3) the detection of functionally active tight-binding inhibitors is
insensitive to their molecular properties (nature, molecular weight, elementary composition, etc.).
In this regard, the term “apparent”, less stringent but practically convenient, is used for all the
functional parameters (inhibitor concentration, Ki, kass, kdiss, etc.) estimated under these circumstances,
given that they represented a heterogeneous population instead of a purified inhibitor.
P. homomalla extract showed for both enzymes sensorgrams with typical association and
dissociation phases and concentration-dependent responses indicative of actual interactions
(Figure 5A,C). Further kinetic analysis of association and dissociation data allowed the determination
of apparent kinetic constants kassapp (1.98 × 106 M−1·s−1), kdissapp (2.67 × 10−3 s−1) and kdissapp/kassapp
(1.35 × 10−9 M) for the interaction of the inhibitor with immobilized FP2, confirming the occurrence
of tight-binding inhibitor in the extract [53]. Similar results were obtained for Plm II, with
the interaction displaying slower association (kaapp = 6.19 × 104 M−1·s−1) and dissociation rates
(kdapp = 5.96 × 10−3 s−1) than in the previous case. The value of kdapp/kaapp (9.64× 10−9 M), equivalent
to the thermodynamic dissociation constant KDapp, also confirmed the occurrence of tight-binding
inhibitor(s) in this extract. In contrast, the extract of X. muta (TCA) showed no or only weak signs of
interaction with immobilized FP2 and Plm II, which confirmed the absence of tight-binding inhibitors
of the target enzymes (Figure 5B,D). Although this technique did not provide information about the
inhibitory effects of the interaction, the kinetic and thermodynamic data obtained, such as affinity, time
required to achieve steady-state and stability of the E-I complex, might be of great value to recognize
potential biomedical or biotechnological applications for the enclosed inhibitor(s) [60,61].
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Figure 5. Evaluation of reference extracts for the identification of target interactors by using
biosensor-based binding assays. Sensorgrams from the SPR-biosensor assay for the interaction of
the heat-clarified extract of: P. homomalla (A); and the TCA-clarified extract of X. muta (B) with Plm II.
Three seri l (1/2) dilutions were analyzed. Sens rgrams from a resonant mirror biosensor assay for the
interaction of the heat-clar fied extr ct of: P. homomalla (C); and the TCA-clarified extract of X. muta
(D) with FP2. Four dilutions were analyzed. In the case of positive interaction (A,C), insets show the
steady state plots.
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IF MALDI-TOF MS was used as another interaction-based technique to confirm the presence
of inhibitors in the selected reference extracts. Protease-inhibitor interactions are detected through
the decrease (fading) of the relative intensities of the m/z signal corresponding to the inhibitor after
the addition of the target protease immobilized to an appropriate support. To confirm the binding,
the formed complexes are then dissociated to regenerate the faded ion signal corresponding to the
inhibitor [51,52]. Analysis of the positive P. homomalla (heat) extract confirmed the existence of several
molecules interacting specifically with Sepharose-immobilized Papain (Figure 6A), corresponding to
m/z+ of 5973.8, 6074.2, 7357.7, 14711.0 and 14736.9 [53]. A similar analysis using Pepsin-Sepharose
allowed us to identify a molecule (m/z+ 5974.4) specifically interacting with Pepsin-like aspartic
proteases (Figure 6B), confirming in both cases the occurrence of binding partners for the targets that
may be responsible for the inhibitory activity detected in the reference extract. The ion signals at
m/z+ 5973.8 and 5974.4 detected, respectively, after specific binding analysis to Papain and Pepsin
may correspond to a bi-functional (and potentially inhibitory) component in the extract, which has
been previously described in marine invertebrates [40,41,44]. It is noteworthy that some ion signals
were also obtained from the analysis of the negative reference X. muta (TCA) extract for both enzymes
(data not shown). This suggests that, although able to be detected by the high sensitivity of MS,
interactors of target enzymes were not inhibitory, too scant or too weak to be detected by the previous
enzymatic assays. In addition to hit confirmation, this technique provided valuable information not
only about the number but also the molecular weights of the potential inhibitors present in the extract,
although it must be complemented with enzymatic activity assays to determine whether the interactors
actually reduce activity of the target enzymes.
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Figure 6. Evaluation of reference (positive) extract for the identification of target interactors by using
Intensity Fading atrix Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry
(IF MALDI TOF MS). (A) MALDI-TOF mass spectra correspond ng to the heat-clarified extract of
P. homomalla (top) nd the elution fraction (bottom) fter the incubation with Pa ain-Sepharose.
(B) MALDI-TOF mass spectra corresponding to the heat-clarified extract of P. homomalla (top) and the
elution fraction (bottom) after the incubation with Pepsin-Sepharose. The peaks corresponding to
specific interactors are highlighted by dotted arrows.
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Noteworthy, our validation experiment using reference extracts of marine organisms are in good
agreement with previous studies [46,47,53]. Although performed under different conditions, Plm II
and FP2 activity assays clearly identified S. helianthus and P. homomalla as the most promising extracts
against both enzymes, whereas P. nigra and P. constellatum showed the expected low potential. Their
combination with binding assays further confirmed the existence of compounds specifically interacting
with the target enzymes in the positive extracts and also allowed differentiation between negative
and false negative hits (such as the heat-clarified extract of X. muta against Plm II). Taken together,
our results validate not only the conditions established for individual screening assays, but also the
proposed strategy; allowing its application to the large scale screening of Plm II and FP2 tight-binding
inhibitors in aqueous extracts of marine invertebrates.
2.2. Massive Screening of Aqueous Extracts of Cuban Marine Invertebrates
A heterogeneous immuno-enzymatic Plm II assay [31] was used for the primary screening of 35
clarified aqueous extracts (Table 1), given its high-throughput compatible format. P. homomalla (heat),
S. helianthus (heat and TCA), P. nigra (heat and TCA) and X. muta (heat) extracts, previously used as
reference extracts to validate the strategy, were included in the screening to evaluate the consistency of
our results. Seventeen clarified extracts (~49%) caused DU2 degradation levels (≥30%) incompatible
with the enzymatic assay and were excluded from further evaluation (Figure S2, Supplementary
Material). All the remaining extracts decreased in some level the enzymatic activity of Plm II,
with values ranging from 27.7% to 94.0%. Only five extracts caused reduction levels higher than 75%
and were considered positive hits (Figure 7A). Therefore, all of them (except P24 due to ambiguous
initial classification and stock depletion) were considered for the confirmatory round without the
need to perform a secondary screening. In addition, extracts P31 and P32 showed highly potent and
reproducible Plm II inhibitory activity, in contrast to P7 and P11 that suffered inconsistencies among
different isolates [46].
Table 1. Names and Phylum distribution of the species included in this study. The identifiers
(F: Falcipain 2; P: Plasmepsin II) used to distinguish each extract are indicated. The clarification
treatment used in all cases was heating at 60 ◦C for 30 min unless otherwise indicated. Those extracts
causing reduction levels equal or higher to 75% (hits) during primary screening are indicated by (+),
and those further validated by interaction-based assays are indicated by (++). w.b.: whole body;
s.: spikes; g.: gonads; b: body; b.c.: branchial crown; p.c.: polyps and coenenchyme; —: not tested.
Species Phylum
Identifier
Falcipain 2 Plasmepsin II
Hermodice carunculata Annelida F30 (+) —
Sabellastarte magnifica (b.c.) Annelida F22 —
Sabellastarte magnifica (b.) Annelida F23 —
Bugula plumosa Bryozoa F39 P25
Copidozoum sp. Bryozoa — P24 (+)
Zoobotrium sp. Bryozoa — P30
Zoobotrium sp. (TCA clarified) Bryozoa — P33
Ascidia sydneiensis Chordata F31 —
Ascidia sydneiensis (TCA clarified) Chordata F44 P28
Diplosoma listerianum Chordata F33 —
Ecteinascidia turbinata Chordata F28 —
Microcosmus sp. Chordata — P15
Phallusia nigra Chordata F21 —
Phallusia nigra (TCA clarified) Chordata F45 —
Acetabularia sp. Chlorophyta — P17
Bryopsis pennata Chlorophyta — P21
Halimeda opuntia Chlorophyta F34 —
Penicillus capitatus Chlorophyta — P9
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Table 1. Cont.
Species Phylum
Identifier
Falcipain 2 Plasmepsin II
Bartholomea annulata Cnidaria — P11 (++)
Bunodosoma granulifera Cnidaria F11 (+) P8
Bunodosoma granulifera (TCA clarified) Cnidaria F32 (++) —
Cassiopeia xamachana Cnidaria — P29
Condylactis gigantea Cnidaria F3 (+) —
Condylactis gigantea (TCA clarified) Cnidaria F29 —
Eunicea calyculata Cnidaria — P13
Lenubrea danae (p.c.) Cnidaria F16 —
Lenubrea danae (w.b.) Cnidaria F17 —
Lenubrea danae (w.b.) (TCA clarified) Cnidaria F36 (+) —
Linuche unguiculata Cnidaria F15 (+) —
Palythoa caribbaeorum Cnidaria F2 (+) P5
Palythoa caribbaeorum (TCA clarified) Cnidaria F12 (+) —
Physalia physalis Cnidaria F47 —
Plexaura homomalla Cnidaria F8 (++) P31 (++)
Stichodactyla helianthus Cnidaria F6 (++) P3
Stichodactyla helianthus (TCA clarified) Cnidaria F38 (+) P35
Zhoanthus pulchelus Cnidaria F7 (+) P22
Zhoanthus sp. Cnidaria — P16
Echinaster echinophorus Echinodermata F35 P4
Echinometra lucunter Echinodermata — P23
Eucidaris tribuloides Echinodermata F24 (+) —
Holothuria mexicana Echinodermata F42 (++) P6
Holothuria sp. Echinodermata F37 —
Holothuria sp. Echinodermata — P18
Holothuria sp. Echinodermata — P19
Holothuria sp. Echinodermata — P20
Isostochopus badionotus Echinodermata F26 (+) —
Luidia senegala Echinodermata — P26
Lytechinus variegatus (w.b.) Echinodermata F40 —
Oreaster reticulates Echinodermata — P27
Tripneustes ventricosus (s.) Echinodermata F4 —
Tripneustes ventricosus (g.) Echinodermata F5 (+) —
Tripneustes ventricosus (w.b.) Echinodermata F10 P2
Cenchritis muricatus Mollusca F43 (+) P7 (+)
Nerita peloronta Mollusca F20 (++) —
Nerita versicolor Mollusca F41 (+) —
Purpura patula Mollusca — P12
Ectyoplasia ferox Porifera — P32 (++)
Lissodendorix isodyctialis Porifera F25 (+) P1
Xetospongia muta Porifera F46 P10 *
Xetospongia muta (TCA clarified) Porifera — P34
Galaxaura sp. Rhodophyta F27 (+) —
Laurencia sp. Rhodophyta — P14
* False-negative extract validated by affinity chromatography.
For FP2 tight-binding inhibitor screening, 41 clarified extracts (Table 1) were screened using a
fluorogenic enzymatic assay [12]. At the established dilution (1:20), 14.6% of the clarified extracts
interfered significantly with fluorescence readouts (Figure S2, Supplementary Material). For these
extracts, the calculated coefficient Q was used to correct the experimental slope of enzymatic
assays. In addition, only 2 (~5%) clarified extracts showed appreciable intrinsic proteolytic activity
(∂F/∂t ≥ 5 × 10−4 AFU·s−1) against the Z-FR-AMC substrate and were excluded from further
evaluation. The rest decreased in some level the enzymatic activity of FP2 control, with values
ranging from 7.8% to virtually 100%. In this case, 21 extracts caused reduction levels higher than
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75% and were considered positive hits (Figure 7B). Given the high rate of success (~54%), it was
necessary to include a secondary screening (IC50 estimation) prior to extract validation, to establish
priorities among hits. The same enzymatic assay was used in the secondary screening, as this allowed
the simultaneous evaluation of several clarified extracts in the same run. Although several extracts
showed biphasic dose–response curves suggesting tight-binding inhibition, three (F20, F32 and F42)
displaying low IC50 values were selected for further validation (Figure 7C–E).Mar. Drugs 2017, 15, 123  12 of 25 
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dose–response curves suggesting tight‐binding inhibition, three (F20, F32 and F42) displaying low 
IC50 values were selected for further validation (Figure 7C–E).   
Several non‐enzymatic methodologies, able to detect specific biomolecular interactions directly, 
were alternatively used to confirm the existence of Plm II and FP2 inhibitors in the positive extracts 
Figure 7. Enzymatic screening of Plm II and FP2 inhibitory activity in clarified extracts of marine
invertebrates. Effect of clarified extracts on the activity of: Plm II (A); and FP2 (B) (primary screening).
For both assays, extracts causing reduction levels equal or higher to 75% were considered hits. Hit
thresholds are indicated by dashed li es. Biphasic dose–response curves for ts: F20 (C); F32 (D);
and F42 (E) select d fro secondary screening ag inst FP2. Clarified extr cts selected for confirmatory
experiments are indicated (solid gray). The experiments were all performed in triplicate.
Several non-enzymatic methodologies, able to detect specific biomolecular interactions directly,
were alternatively used to confirm the existence of Plm II and FP2 inhibitors in the positive extracts
selected from primary enzymatic screening. Due to the greater availability of the extracts P31 and
P32, a Plm II-Sepharose affinity column was used. Th typical chromatogram obtained and the
increment observed in specific Plm II inhibitory activity c rroborated the presence of target inhibitors
in both extracts (Figure 8A,B). An SPR-based biosensor assay was used to confirm Plm II interacting
molecules in the extract P11 (extracts P31 and P32 were also included for comparison) (Figure 8C).
The form of the resultant sensorgrams after subtracting unspecific binding (reference cell) indicated
the occurrence of Plm II binding partners in all the extracts, which are probably responsible for the
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inhibitory activity previously observed. In addition, it confirmed the reversibility of the interactions
and indicated markedly different kinetic and thermodynamic properties for the three inhibitors.
Inhibitor from P31 showed faster association and slower dissociation rates than those from P11 and
P32, denoting a lower Ki value for this molecule and indicating a considerably longer inhibitory
effect on Plm II. Moreover, as has been previously shown, IF MALDI TOF MS analysis of P31 using
Pepsin-Sepharose permitted the identification of a single Pepsin-interacting molecule with a MW of
5974 Da, and suggested that the enzyme-inhibitor interaction was reversible, which agreed with
the results from SPR and affinity chromatography experiments. The Plm II inhibitor from P31
(PhPI (Plexaura homomalla Plasmepsin Inhibitor)) was purified to homogeneity by a combination
of affinity chromatography (Plm II-Sepharose) and size exclusion chromatography (Superdex 75,
Pharmacia, Sweden). The purified inhibitor was functionally characterized by using a continuous
chromogenic enzymatic assay [46]. The dose–response curve of PhPI showed titrating behavior
(Figure 8D), suggesting the occurrence of tight-binding inhibition and allowing us to estimate the
concentration of active inhibitor. The use of lower [E0]/K
app
i ratios produced a transition to concave
curves (Figure 8E), which permitted the determination of a Ki value of 4.3 × 10−9 M. This result,
obtained for the purified inhibitor, is in good agreement with that previously estimated by SPR
experiments (KDapp = 9.64 × 10−9 M) despite the higher chemical heterogeneity of the clarified extract;
indicating both the selectivity of SPR methodology and the acceptable accuracy of the estimation of
global (tight-binding) inhibitor concentration by enzyme titration.
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Figure 8. Confirmatory experiments using binding assays for molecules able to interact with Plm II in
the selected extracts. Affinity chromatography profiles of extracts: P31 (A); and P32 (B) with a HiTrap™
Plm II-Sepharose HP resin. Arrows indicate the addition of elution buffer. (C) Sensorgrams from the
SPR biosensor-based assay for the interaction of extracts P11, P31 and P32 with Plm II. (D) Titration
curve of purified PhPI with (pepstatin A-titrated) Plm II used to determine the concentration of active
inhibitor. (E) Concave dose–response curve for the estimation of Kappi of PhPI with Plm II.
Papain-Sepharose affinity chromatography confirmed the existence of FP2 inhibitors in extracts
F32 and F42, as both typical chromatograms and increased specific FP2 inhibitory activity were obtained
(Figure 9A,B). A resonant-mirror optic biosensor confirmed reversible interactions for the inhibitors
present in F20 and F42 with FP2, as well as similar association and dissociation behavior (Figure 9C).
This behavior also proved similar to that shown by the inhibitor present in F8, which previously showed
tight-binding interaction with the target enzyme and a Ki value in the low nanomolar range [53].
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Further information about the inhibitor present in F20 was obtained from IF MALDI TOF MS using
Papain-Sepharose (Figure 9D), which showed a predominant ion signal at m/z+ 6733, indicative of the
molecular mass for the putative inhibitor.
MALDI TOF MS provided additional information about the nature and homogeneity/
heterogeneity of inhibitors here investigated, which used to be small proteins in the 5–15 kDa
mass rage. This has been clearly shown in the above mentioned purified pepsin-like inhibitor from
Plexaura homomalla (PhPI, from P31 identifier), which displayed a molecular mass of 5974 Da by such
approach. A similar case was evident for the papain-like inhibitor found in Stichodactyla helianthus
(heat clarified, F6 identifier) which showed a molecular mass of 6113 and which, after MS/MS
fragmentation by either ISD and/or CID approaches, displayed derived sequences of fragments
that fully matched with the internal ones of the previously reported protein inhibitor found in such
species [46]. Figure S4 illustrates such case.
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Figure 9. Confir atory experi ents using binding assays for molecules able to interact with Papain-like
cysteine proteases in the selected extracts. Affinity chromatography profiles of extracts: F32 (A); and F42
(B) with a Papain-Sepharose resin. Arrows indicate the addition of elution buffer. (C) Sensorgrams
from the biosensor-based assay for the interaction of extracts F20 and F42 with FP2. Reference
extract F8 (positive) was included for comparison. (D) Matrix Assisted Laser Desorption/Ionization
Time-Of-Flight (MALDI-TOF) mass spectra corresponding to the clarified extract F20 (top) and the
lution fracti n (bottom) after the incubation with Papain-Sepharose.
3. Discussion
The identification of tight-binding inhibitors from natural marine sources for prototypic
pepsin-like and papain-like protease is of great interest, given the increasing number of applications
for such bioactive molecules in biomedicine, biotechnology and industry. However, only few studies
addresses the methodological complications of the identification of genuine protease inhibitors in
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highly heterogeneous natural extracts, a factor we presume critical for the success of screening
campaigns. In this regard, this work presents a strategy for the identification and prioritization
of complex natural extracts enriched in Plm II and FP2 tight binding inhibitors as a source for
the isolation of potentially new bioactive compounds. The potency of the present strategy derives
from the combination of medium-to-high throughput enzymatic assays with a variety of orthogonal
interaction-based techniques, resulting in increased identification confidence, higher robustness to
interferences and the ability to process a moderate number of natural extracts with low cost.
Both initial validation with five reference extracts and the following screening with 62 invertebrate
extracts revealed some of the benefits of the selected approach. The inclusion of reference extracts
in both enzymatic screenings confirmed the consistency of the results. During FP2 screening,
all the reference extracts showed the same behavior as in the previous validation experiments.
The same occurred during Plm II screening for the extracts of P. homomalla (heat)/P31, and X. muta
(heat)/P10. Divergent results were only observed for S. helianthus heat- and TCA-clarified extracts.
The heat-clarified extract (P3) showed high intrinsic proteolytic activity on DU2 and was excluded
from screening, whereas TCA-clarified extracts (P35) inhibited ~55% of Plm II control, thus appearing
negative according to our cut-off criteria. Further studies would be necessary to unravel the specific
causes of these differences, although the occurrence of batch to batch variations in the balance of
proteolytic/inhibitory activities is common in marine invertebrates as a consequence of biological,
seasonal and environmental factors [39].
The selection of a hit threshold of 75% had a positive impact on the effectiveness of the screening
as this allowed us to distinguish only those extracts with higher potential in terms of concentration
and/or potency of the desired inhibitors. This was particularly important in our case, since not all the
hits could be studied in parallel due to practical and economical limitations. A common definition of hit
in screening assays is any activity measurement that is at least N (typically N = 3) standard deviations
away from the mean of control measurements [62]. For the enzymatic assays used in this work, N = 3
would correspond to set hit threshold ~25% (Figure S3A). At this condition, the number of hits would
be 18/18 for Plm II and 34/39 for FP2 (Figure S3B). This means that practically all the assessed extracts
were able to reduce the activity of the target enzymes on the reporter substrates, statistically differing
from the negative controls with a confidence >99%. However, from a biological point of view, it seems
very unlikely that all of them carry specific inhibitors for the target enzymes, especially of high affinity.
More probably, many of them simply might have alternative substrates for the reporter enzyme or
weak inhibitors with low general interest, which probably would be eliminated during the secondary
screening or the confirmation round using binding assays. In contrast, the selected 75% (which would
correspond to N = 14.3 and N = 8.8 for Plm II and FP2, respectively), decreased the chance of false
positives, represented a more realistic biological scenario and resulted in a better balance between
positive and negative extracts to handle in practice.
Although the binding methodologies used in the study are individually sufficient to confirm the
existence of target interactors, when possible, we used more than one for the most promising extracts
since each technique provided different and somehow complementary information about the inhibitor
or the interaction. Affinity chromatography provided direct evidence of the presence and reversibility
of interacting compounds actually inhibiting the target enzymes, with the additional feature of being
economically accessible to any laboratory. SPR-biosensor allowed studying not only the reversibility
of the protease-ligand interaction, but also its kinetic and thermodynamic behavior. As observed
in several cases along this study, the true values of kinetic and thermodynamic constants could not
be determined, as inhibitor preparations were not pure. However, even under these circumstances,
this technique is able to provide at least preliminary, comparative and behavioral information from the
inhibitors present in different extracts, and therefore, it is useful. For instance, the time required to
establish the steady state and the slope of the association phase may be related to the global rate of
formation of the E-I complexes, whereas the time required for returning to the baseline is related to
dissociation rates and the stability of the E-I complexes. Taken together, these elements may provide
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fair evidence of the existence of tight-binding interactors of the target enzyme in natural extracts,
although it must be complemented with functional enzymatic evidence to confirm target inhibition.
Moreover, IF MALDI TOF MS provides information about the potential number of putative
interactors, their molecular masses and their peptide/proteinaceous nature, which is critical to design
appropriate purification protocols. As a consequence of the extraction with aqueous solutions and
the clarification treatments introduced here, the proportion of extracted protease inhibitors is largely
biased to polypeptides and proteins, in detriment of secondary metabolites (which are more likely
to be extracted by mixtures of organic solvents with mid-to-low polarity). This fact complicates the
determination of the detailed molecular structure for these inhibitors, as relatively large amounts of
pure (i.e., recombinant) proteins are required for NMR or crystallization experiments. However, given
the high sensitivity of MS, this technique may still provide valuable information regarding the primary
structure of the putative inhibitor by fragmentation of the intact protein (Top-Down sequencing) or
some of its peptides (Bottom-Up sequencing) [63].
Altogether, our findings highlight the aqueous extract of Cuban marine invertebrates as a
prominent source for the identification of novel tight-binding (peptidic) inhibitors for pepsin-like and
papain-like model proteases, such as P. falciparum enzymes Plm II and FP2. Interestingly, the number
of hits against the cysteine hemoglobinase FP2 was significantly higher than those for the aspartyl
protease Plm II, suggesting a more ubiquitous distribution of cysteine protease inhibitors in marine
invertebrates. This is in good agreement with the relative abundance of both protease classes [64] and
with unpublished observations of our group in previous screenings against other aspartyl and cysteine
endopeptidases. Combining the results from both enzymes, the Phyla with the higher positivity ratios
were Mollusca (4/5), Cnidaria (13/25) and Porifera (3/6) in this order, backing a role for these molecules
in the regulation of endogenous proteases and/or their participation as mechanisms of chemical
defenses against predation or in the innate immune response against pathogens [38,39]. A previous
screening study against prototypic proteases belonging to different mechanistic classes highlighted
the high frequency of protease inhibitors in Cnidarians [47]. A more comprehensive study, covering
a variety of enzymes and marine species belonging to several Phyla, also showed similar results
(Covaleda, Avilés and Chávez, unpublished results), confirming the validity of the data obtained here.
There are numerous examples of the medical-clinical applications of protease inhibitors [1,3],
including their use in infectious diseases [65,66]. However, in most cases the small size or molecular
mass and synthetic forms are favored over the high mass ones, usually protein forms, which are
very frequent states for natural inhibitors. Such tendency is mainly due to the lower cost, easier
obtainment, higher storage stability and lower probability of anaphylactic reactions of the former.
However, the large proteinaceous protease inhibitors, quite distributed in nature, frequently display
useful specificities and other biological-biomedical properties difficult to be attained by the small forms,
a fact which promoted proposals and attempts for using them as drugs, diagnostic or imaging reagents.
Among such cases are hirudin (from leeches), 1-antitrypsin, 2-antiplasmin and aprotinin/trasylol/BPTI
(from human or mammals), other serpins, TIMPs and cystatin C (human forms), ecotin (from E. coli),
BBI (from soya beans), etc., the first four particularly used for coagulation and fibrinolytic disorders [67].
In any case, the large natural inhibitors have been and are useful models to identify both the active site
and exosite motifs of the target proteases, and are considered as lead compounds to much smaller forms
by minimization, truncation and other ways to reduce the size whilst keeping the functionality [1,3].
To the moment, several aspartic and cysteine protease inhibitors have been complete or partially
purified from the validated extracts [46], and others are currently under characterization. Even as
enriched fractions, some of them have proven their potency as antiparasitic agents (enriched fraction
of F8) against P. falciparum and Trypanosoma cruzi (the causative agents of the most deadly malaria
and Chagas diseases) [53]. Further studies are needed to complete the molecular and functional
characterization of such inhibitors, including complete amino-acidic sequence and selectivity toward
related human proteases.
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4. Materials and Methods
4.1. Collection of Marine Organisms. Preparation and Clarification of Aqueous Extracts
Marine organisms belonging to different Phyla (Table 1) were screened for inhibitory activity
against Plm II and FP2. Specimens were identified “in situ” and collected by snorkeling and scuba
diving from major marine habitats (seagrass beds, mangroves, coral reefs, sand bottoms and rocky
coasts), from low tide to a depth of 10 m, in various locations along the northwest Cuban coast from
Havana to Puerto Esperanza (Pinar del Río). All the collections were carried out during the boreal
summer season (from the months of July to September).
Crude aqueous extracts were prepared by homogenizing the whole body or selected part of
the wet specimen in distilled water (1:2 w/v) followed by centrifugation (10,000× g, 30 min, 4 ◦C).
For clarification, the extracts were heated (60 ◦C, 30 min) and centrifuged (15,000× g, 30 min, 4 ◦C) to
eliminate insoluble and thermolabile components. Alternatively, the crude extracts were treated with
5% final concentration of trichloroacetic acid, followed by centrifugation (15,000× g for 30 min at 4 ◦C),
the supernatant was adjusted to pH 7.0 with 1 M NaOH and dialyzed (O.N., 4 ◦C) against distilled
water (1:100 v/v) using membranes with a MW cut-off of 500 Da. The clarified extracts were kept at
−20 ◦C until use. In all cases, total protein content was determined by the Bradford assay (Bio-Rad,
Hercules, CA, USA).
4.2. Expression, Purification and Refolding of Plm II and FP
Plm II and FP2 were expressed as inclusion bodies in BL21(DE3)pLysS and BL21(DE3) E. coli
strains, respectively; purified under denaturing conditions; and refolded to active enzymes as
previously described [46,68].
4.3. Enzymatic Assays
4.3.1. Plasmepsin II
A heterogeneous immunoenzymatic assay was used for the primary screening of Plm II
inhibitors in clarified extracts using the biotinylated peptide DU2 (Biotin-βAβALERTF→
LSFPRQSTPIGLGQALYTT-COOH) as substrate (KM: 1.6 µM; kcat: 3.5 × 10−3 s−1; kcat/KM:
2.2 × 103 M−1·s−1; Signal sensitivity: 4.4 × 1013 AU·mol−1) [31]. In brief, 96-well microtiter plates
are coated with streptavidin. After blockade, plates are sensitized by the addition of the N-terminal
biotinylated synthetic peptide DU2, which also comprises a Plm II cleavage sequence and a C-terminal
epitope specifically recognized by a monoclonal antibody. After the addition of Plm II, the LERTFLSFP
sequence in DU2 is recognized and hydrolyzed by the enzyme at the F–L bond, releasing the C-terminal
epitope (RQSTPIGLGQALTYTT) which is washed away. The amount of non-degraded DU2 can then
be estimated by a typical ELISA procedure, resulting in relatively low OD492nm readouts when Plm II
activity is high; or high OD492nm readouts when Plm II is absent or effectively inhibited [31].
To evaluate the presence of interferences (e.g., proteinases that degrade DU2), clarified extracts
(final dilution 1/2) were incubated for 2 h at 37 ◦C in 100 mM NaAc, pH 4.7 buffer with DU2-sensitized
plates to evaluate their ability to degrade the immobilized substrate. Those extracts showing
degradation levels equal or higher to 30% were excluded from the primary screening for inhibitors.
The selected clarified extracts were pre-incubated for 10 min with Plm II (0.37 µM) at 37 ◦C in
100 mM NaAc pH 4.7 buffer, followed by incubation for 2 h with DU2-sensitized 96-well microtiter
plates. The OD492nm was recorded in a Multiskan EX plate reader (Labsystems) and data were
mathematically processed as indicated by Salas et al. [31]. Extracts that caused a decrease in
Plm II activity equal or higher to 75% were considered hits. All the assays were performed
in triplicate. For the kinetic characterization of Plm II inhibitors, a continuous enzymatic assay
was performed using Leu-Ser-Phe(NO2)-Nle-Ala-Leu-OMe (215 µM) as substrate (KM: 27.4 µM;
kcat: 10.4 s−1; kcat/KM: 3.8 × 105 M−1·s−1; Signal sensitivity: 1.0 × 103 AU·M−1) [46]. For this assay,
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Plm II (0.119–0.207 µM) was pre-incubated with the inhibitors for 10 min at 37 ◦C in 100 mM NaAc
pH 4.4 prior the addition of the substrate. The reactions were followed at 310 nm in an Ultrospec
4000 kinetic spectrophotometer (Pharmacia Biotech, Cambridge, UK). All the assays were performed
in triplicate.
4.3.2. Falcipain 2
For FP2, the primary screening, the secondary screening and the characterization of partially
purified inhibitors were performed with a fluorogenic enzymatic assay described previously,
using Z-FR-AMC (12.5 µM) as substrate (KM: 9.1 µM; kcat: 0.4 s−1; kcat/KM: 4.5 × 104 M−1·s−1;
Signal sensitivity: 1.8 × 105 AFU·M−1) [12]. To evaluate the interferences, clarified extracts
(final dilution 1/20) were mixed with an AMC standard and its ability to modify the AMC fluorescence
(λexc/λemss = 355 nm/460 nm) was monitored. For those samples with Q = FAMC/FAMC+EXT 6= 1,
the calculated coefficient Q was used to correct the value of experimental slope. The ability of clarified
extracts (final dilution 1/20) to hydrolyze Z-FR-AMC (12.5 µM) was evaluated in 100 mM NaAc,
10 mM DTT pH 5.5 buffer. Those extracts showing slopes equal or higher to 5 × 10−4 AFU·s−1 were
excluded from the screening.
Primary screening: Selected clarified extracts were initially pre-incubated 10 min at 37 ◦C with
FP2 (0.95 µM) in 100 mM NaAc, 10 mM DTT pH 5.5 buffer and Z-FR-AMC (12.5 µM) was added to
start reaction. Slopes in the linear region of progression curves were calculated and transformed into
percentages of reduction in FP2 activity. Those extracts showing reduction levels equal or higher to
75% were considered positive hits and evaluated in a secondary screening.
Secondary Screening: All the assays (final volume 200 µL) were carried out in Greiner (black)
96-well microtiter plates and the fluorescence was recorded in a DTX 880 Multimode Reader (Beckman
Coulter, Fullerton, CA, USA), except for the estimation of Ki, which was carried out by using a
single-cuvette AMINCO-BOWMAN SERIES 2 luminescence spectrofluorometer (Thermo Spectronic,
Madison, WI, USA). Inhibition for at least 6 different inhibitor concentrations was detected through
the decrease in residual activity (a), which is calculated by Equation (1):
a = vi/v0 (1)
where vi and v0 are the initial rates of the reaction in the presence and absence of the inhibitor,
respectively. The IC50 values (concentration of the inhibitor required to inhibit the enzyme by 50%)
were estimated by fitting the Equation (2) [57] to experimental data from dose–response curves by
using the GraphPad Prism program (version 5.03).
vi/v0 = 1/(1+ [I]/IC50) (2)
4.4. Estimation of the Active Concentration of Inhibitors by Titration with Enzymes
The continuous assays described for Plm II and FP2 were used to estimate the active concentration
of the inhibitors. The enzymes Plm II and FP2 were previously titrated with Pepstatin A and E-64,
respectively, under experimental conditions ensuring titrant behavior ([E0]/K
app
i ≥ 10). Under these
conditions the dose–response curve shows a biphasic behavior typical of tight-binding inhibitors.
Residual enzymatic activity (a, Equation (1)) was evaluated after pre-incubation for 10 min of the
enzyme with at least 6 different inhibitor concentrations. The titration volume was estimated by
extrapolating the linear portion of curve (1> a >0.2) to the x-axis. The active concentration of the
enzyme was calculated assuming a stoichiometric ratio 1:1 by using Equation (3):
[E]ACT = [I]ACT ·VolASSAY/VolTITRATION (3)
where [E]ACT and [I]ACT are the concentration of active enzyme and inhibitor, respectively, whereas
VolASSAY is the volume of the reaction mix and VolTITRATION is the volume of inhibitor required to
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completely abolish the activity of the enzyme. Titrated Plm II (0.207 µM) and FP2 (0.189 µM) were
used to titrate the purified inhibitors using the same approach used to titrate the enzymes.
4.5. Kinetic Estimation of Ki Values
The continuous enzymatic assays described above were used to estimate the Ki values of natural
inhibitors against Plm II and FP2. Inhibition constants (Ki) were determined by measuring the residual
enzymatic activity (a) by the use of Equation (1). Kappi values were calculated by fitting the experimental
data from concave dose–response curves to the Equation (4) for tight-binding inhibitors [56]:
a = 1−
([E0] + [I0] + K
app
i )−
√(
[E0] + [I0] + K
app
i
)2 − 4[E0] · [I0]
2[E0]
(4)
where a is the residual enzymatic activity, and [E0] and [I0] are the total concentrations of enzyme and
inhibitor, respectively. In all cases, the Kappi values were corrected according to the Equation (5) [56].
Kappi = Ki · (1+ [S0]/KM) (5)
Nonlinear regression analysis was performed by using the Statistica software for Windows
(version 6.0, 2001; StatSoft, Tulsa, OK, USA).
4.6. Generation of the Immobilized Enzyme Support
The Glyoxyl-Sepharose derivative was prepared as described in [69]. In brief, Sepharose 4BCl
was mixed by gentle stirring with ice-cold 750 mM NaBH4, 1.7 M NaOH solution. Glycidol was added
drop-to-drop to the mixture and kept under gentle stirring for 12 h at 4 ◦C. After several washes with
distilled water, 0.1 M NaIO4 was added to the Glyceryl-Sepharose gel. After 2 h of continuous mixing
in darkness, the Glyoxyl-Sepharose derivative was collected by filtration, extensively washed with
distilled water and conserved at 4 ◦C. For immobilization, Papain was coupled to Glyoxyl-Sepharose
4BCl through its amine groups at a 10 mg per-mL-of-gel ratio. The immobilization reaction was
performed at RT in 100 mM sodium borate pH 10.0 buffer with gentle O.N. stirring at 4 ◦C. For further
reduction, NaBH4 (14.8 mg per-mL-of-gel ratio) was added to the reaction mixture and finally,
the resultant resin was washed several times with alternate cycles of pH 5.0/pH 8.8 buffers.
The immobilization of porcine Pepsin on NHS-activated Sepharose 4 Fast Flow (GE Healthcare,
Buckinghamshire, UK) was performed using a procedure described previously [46]. Briefly, Pepsin
was mixed with NHS-activated Sepharose at 5 mg-per-mL-of-gel ratio. Immobilization reaction was
performed at RT in 20 mM Hepes pH 7.4 under gentle O.N. mixing. Ethanolamide (0.2 M, pH 8.0) was
used for blocking the remaining active groups on the matrix and finally the resin was washed several
times with alternate cycles of pH 4.4/8.0 buffers.
On the other hand, a preparative column for Plm II affinity chromatography was obtained by
immobilization of Plm II on a pre-packed HiTrap™ NHS-Sepharose HP column (GE Healthcare,
Buckinghamshire, UK) following the manufacturer’s instructions. Plm II was coupled to the matrix
by applying a protein solution (8 mg total) to a 5 mL HiTrap™ NHS-Sepharose HP column at a flow
rate of 0.5 mL/min. Coupling reaction was performed at RT in 0.2 M NaHCO3, 0.5 M NaCl pH 8.3 for
30 min. Finally, the column was washed with alternate cycles of 0.5 M ethanolamide, 0.5 M NaCl pH
8.3 and 0.1 M NaAc, 0.5 M NaCl pH 4.0 solutions.
4.7. Validation Experiments by Affinity Chromatography
The affinity chromatography with the HiTrap™ Plm II-Sepharose HP column (5 mL) was
performed in an Äkta purifier system (GE Healthcare, Buckinghamshire, UK). Clarified extracts of
selected hits were applied to the column previously equilibrated with 20 mM NaAc, 150 mM NaCl
pH 4.4. After an exhaustive washing with the equilibration buffer to remove unspecific interactions,
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the bound molecules were eluted using 50 mM glycine pH 9.0 and neutralized with 1 M NaAc pH 4.4.
Fractions from the different steps were collected for further Plm II inhibition analysis.
For Papain-binding analysis, clarified extracts of selected hits (10 mL) were circulated through
1 mL of a Papain-Sepharose support packed in a PD10 column and previously equilibrated with
100 mM NaAc, 150 mM NaCl, pH 5.5. After washing with sufficient volume of equilibrium buffer
to reduce the OD280nm to the base line, the retained components were eluted from the column with
100 mM Na2HPO4, 2 M NaCl pH 9.5 and immediately neutralized with 1 M NaAc pH 5.5. The fractions
from the different steps were collected for further FP2 inhibition analysis.
4.8. Validation Experiments with Optical Biosensor
The analyses of the interaction of inhibitors with immobilized Plm II were performed at 25 ◦C
on a Biacore X system (Biacore AB, Uppsala, Sweden). A 20 mM NaAc, 150 mM NaCl, 3 mM EDTA,
pH 4.4 solution was used as running buffer. Purified Plm II and bovine serum albumin (BSA, used as
reference) were immobilized on a carboxymethylated Sensor Chip CM5 (Biacore AB) by direct coupling
to primary amines in 5 mM NaAc, pH 4.4 following the manufacturer’s instructions. For the binding
experiments, a continuous flow of running buffer (50 mM NaAc, 150 mM NaCl, pH 4.4) at 10 µL/min
was used, and binding responses were recorded continuously. Each 40 or 50-µL sample (final extract
dilution 1/10) was injected to allow a 4–5 min association phase. After switching back to running
buffer, dissociation was followed for 5–10 min. The BIAevaluation software (version 3.0, Biacore
AB, Uppsala, Sweden) was used for data evaluation and estimation of apparent kinetic association
(kaapp) and dissociation (kdapp) rate constants. The apparent parameter kdissapp/kassapp, equivalent to the
thermodynamic constant KDapp, was arithmetically determined.
Kinetic analyses of interaction between FP2 and the inhibitor(s) present in pre-selected extracts
were performed using an IAsys Biosensor instrument (ThermoLabSystems, Cambridge, UK). Purified
FP2 was immobilized in 10 mM NaAc pH 4.0 on a carboxymethylated dextran layer (CMD cuvettes)
using EDC/NHS chemistry following the manufacturer’s instructions (8–15 ng of active enzymes
were immobilized in a typical experiment). For qualitative validation of pre-selected hits, extracts
(final dilution 1:4000 in 50 mM NaAc, 150 mM NaCl, pH 5.5) were added to the cuvette and the
association phase was recorded at 25 ◦C for approximately 5 min. The extract was then substituted by
running buffer to collect dissociation data. For kinetic constant determination, binding curves were
recorded for at least 6 different concentrations. Apparent kinetic association (kassapp) and dissociation
(kdissapp) rate constants were calculated separately by fitting the equations of monophasic association
and dissociation models to experimental data using the FASTfit software (ThermoLabSystems).
Apparent equilibrium constants (KDapp) were determined by direct analysis of binding curves using
equilibrium response data.
4.9. Validation Experiments by Intensity Fading MALDI-TOF MS
The experiments for the validation of selected hits were carried out by using the IF MALDI-TOF
MS approach, as previously reported [52,70] using the prototypical enzymes Papain and porcine
Pepsin immobilized to Sepharose 4BCl and NHS-activated Sepharose 4 Fast Flow, respectively. In the
experiment, 100 µL of the pre-selected extract was mixed with 100 µL of interaction buffer 2× and
100 µL of enzyme-Sepharose suspension. After 10 min incubation at RT, the resin was collected by
centrifugation and washed with 100 µL of interaction buffer (four times). Finally, the interacting
molecules were eluted by changing the pH. Every fraction (sample, flow-through, every wash and
eluate) was independently analyzed by MALDI-TOF MS. For Papain assay, 100 mM Na2HPO4,
100 mM KCl, 0.1 mM EDTA, 3 mM DTT, 0.05% Brij 35, pH 6.5 was used as interaction buffer and TFA
0.1% for the elution step, whereas for Pepsin assay the interaction buffer was 50 mM NaAc, pH 4.0,
and the elution of the bound molecules was carried out in successive steps using 100 µL of 0.1% TFA,
100 µL of 1% NH4OH and 100 µL of H2O:ACN:TFA (65.9:33:1), respectively.
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All samples were mixed with a matrix solution (1:1, v/v) of 10 mg·mL−1 sinapinic acid
(Bruker Daltonics, Bremen, Germany) dissolved in H2O:ACN:TFA (65.9:33:1); 0.5 µL of the mixture
was spotted onto the MALDI-TOF groundsteel plate by using the dried-droplet method. Mass spectra
were acquired in an UltrafleXtrem mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped
with a smartbeam™ II laser in linear-mode geometry under 20 kV and 1000 laser shots. A mixture of
proteins from Bruker Daltonics (protein calibration standard I; mass range 3000–25000 Da) was used as
a standard.
4.10. Purification of Plexaura homomalla Plasmepsin Inhibitor (PhPI) by PlmII Affinity- and
Size-Exclusion Chromatography
For the affinity chromatography purification step, 5 mL of 10× equilibrium buffer (200 mM NaAc,
1.5 M NaCl pH 4.4) was added to 45 mL of the TCA-clarified extract of P. homomalla. The sample was
loaded (linear flow rate: 12 cm/h) onto a HiTrap™ Plm II-Sepharose HP (5 mL) column, previously
equilibrated with 20 mM NaAc, 150 mM NaCl pH 4.4 using an Äkta purifier system (GE Healthcare,
Buckinghamshire, UK). After an exhaustive washing with the equilibrium buffer to remove unspecific
interactors, the bound molecules were eluted (linear flow rate: 30 cm/h) using 50 mM glycine pH
9.0 and neutralized with 1 M NaAc pH 4.4. Fractions carrying Plm II inhibitory activity were pooled,
lyophilized and solubilized in buffer 20 mM Tris-HCl, 150 mM NaCl pH 8.0. For size-exclusion
chromatography purification step, the sample was loaded onto a Superdex 75 HR 10/30 column
(Pharmacia, Sweden), previously equilibrated with buffer 20 mM Tris-HCl, 150 mM NaCl pH 8.0.
The chromatographic run was performed on an Äkta purifier system using the same buffer at a linear
flow rate of 74.6 cm/h. Fractions containing PhPI were pooled, dialyzed against abundant distilled
water, lyophilized and stored at −20 ◦C until used.
5. Conclusions
As we have shown in this study, the aqueous extracts of marine invertebrates are a promising
source of novel, tight-binding and peptidic/proteinaceous protease inhibitors for cysteine and, to a
lesser extent, aspartic proteases (such as the P. falciparum hemoglobinases FP2 and Plm II), with Cnidaria,
Mollusca and Porifera as the most prominent Phyla. Methodologically speaking, the combination of
interaction-based (affinity/Surface Plasmon Resonance/and IF MALDI TOF MS) and enzymatic
activity assays conveniently tuned, resulted in an efficient, powerful and versatile strategy to make
a confident identification of those extracts carrying tight-binding protease inhibitors. This strategy
can be easily adapted to other target enzymes and has, therefore, a high potential for improving the
identification of tight-biding inhibitors from natural marine sources for a great variety of applications.
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Plm II class-specific protease inhibitors.
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Abbreviations
The following abbreviations are used in this manuscript:
ACN acetonitrile
AFU arbitrary fluorescence units
AMC 7-amino-4-methyl coumarin
AU absorbance units
CMD carboxymethyl dextran
DU2 PlmII-related peptide for immunoenzymatic assays
E. coli Escherichia coli
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
EI enzyme-inhibitor complex
E-64 trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
FP2 falcipain 2
IC50 half-maximal inhibitory concentration
IF intensity fading
MALDI-TOF matrix assisted laser desorption/ionization time-of-flight
MS mass spectrometry
MW molecular weight
NaAc sodium acetate buffer
NHS N-hydroxysuccinimide
OD Optical density
O.N. overnight
PhPI Plexaura homomalla plasmepsin inhibitor
Plm II plasmepsin II
RT room temperature
SPR surface plasmon resonance
TCA trichloroacetic acid
TFA trifluoracetic acid
Z-FR-AMC benzyloxycarbonyl-Phenyl-Arginyl-7-amino-4-methyl coumarin
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